title: Cisplatin-based chemotherapy for stage II ovarian adenocarcinoma: a preliminary report.
abstract: We have performed three sequential trials in patients with FIGO stage II ovarian cancer in an attempt to improve long-term survival. The first trial utilized whole-abdomen radiation and a pelvic boost and the second study utilized pelvic radiation plus melphalan chemotherapy. These trials resulted in estimated 5-year survivals of 40 and 50%, respectively (Gynecol. Oncol. 23, 168-175, 1986). In the current study, 20 patients were treated with 6 months of adjuvant cisplatin-based chemotherapy. The estimated progression-free survival was only 45%. However, by tailoring salvage therapy to the findings at second-look laparotomy, the estimated 5-year survival was 77%. Notwithstanding the latter result of 77%, improved therapy is still required for the relatively rare patient who has stage II ovarian cancer.
authors: Department of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, New York 14263.
authors: M S
authors: MS
authors: Piver
authors: J
authors: J
authors: Malfetano
authors: R E
authors: RE
authors: Hempling
authors: T R
authors: TR
authors: Baker
authors: D L
authors: DL
authors: Driscoll
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007813:Laparotomy; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D012086:Reoperation; D016019:Survival Analysis
chemical_list: D002945:Cisplatin